AvenCell

AvenCell Therapeutics is a clinical-stage biotechnology company developing next-generation allogeneic CAR-T cell therapies for blood cancers. The company’s technology combines healthy donor-derived, gene-edited T cells with a switchable targeting system designed to give physicians greater control over CAR-T activity. Unlike traditional CAR-T therapies that are manufactured individually from a patient's own cells, AvenCell's approach is designed to provide an off-the-shelf therapy that can be available when patients need treatment.